ClinConnect ClinConnect Logo
Search / Trial NCT05810727

Atrial Fibrillation Data Linkage Non-Interventional Study

Launched by PFIZER · Mar 31, 2023

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

ClinConnect Summary

The Atrial Fibrillation Data Linkage Non-Interventional Study aims to explore how the characteristics and effects of atrial fibrillation (AF) change over time. Atrial fibrillation is a common heart condition where the heart beats irregularly or too fast. This study will analyze existing patient data from a specific hospital and national health records in Korea to gain insights into this condition's impact on patients. It's important to note that this study will not involve recruiting new patients; instead, it will focus on information already collected.

To be eligible for this study, participants must have been diagnosed with atrial fibrillation at a hospital or clinic in Korea between January 2010 and December 2020, and they should be at least 18 years old. However, individuals with certain heart valve diseases will not be included in the study. Since this is a data analysis study, participants will not have to attend appointments or undergo any new treatments—it's all about understanding how atrial fibrillation affects people over time using the information already available.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients had incident AF diagnosis (International Classification of Diseases 10th Revision \[ICD-10\]; I48) in an inpatient or outpatient setting at SNUH between 1 Jan 2010 and 31 Dec 2020
  • Patients aged 18 years or older on the index date
  • Exclusion Criteria:
  • Medical claims indicating a diagnosis code indicative of rheumatic mitral valvular heart disease, mitral valve stenosis, or prosthetic heart valve during 12 months period prior to first AF diagnosis

About Pfizer

Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.

Locations

Patients applied

0 patients applied

Trial Officials

Pfizer CT.gov Call Center

Study Director

Pfizer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials